Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy

被引:0
作者
Mario Scartozzi
Mirco Pistelli
Alessandro Bittoni
Riccardo Giampieri
Eva Galizia
Rossana Berardi
Luca Faloppi
Michela Del Prete
Stefano Cascinu
机构
[1] Università Politecnica delle Marche,Clinica di Oncologia Medica, AO Ospedali Riuniti
[2] Università Politecnica delle Marche,Scuola di Specializzazione in Oncologia
[3] Oncologia Medica,undefined
[4] Ospedale “Profili”,undefined
来源
Current Oncology Reports | 2010年 / 12卷
关键词
Gastric; Cancer; Chemotherapy; Adjuvant; Metastatic; Biological; Drug; Antibody; TKI; Perioperative; Neoadjuvant;
D O I
暂无
中图分类号
学科分类号
摘要
Although recent advances have been made, surgery still remains the mainstay of any curative treatment for gastric cancer patients, with radical gastrectomy representing the procedure of choice. However, patients with locally advanced disease show high rates of locoregional or distant recurrence even after potentially curative resections. According to global results presented in the setting of locally advanced resectable gastric carcinoma, perioperative chemotherapy may be considered a valuable option. On the other hand, clinical trials for advanced gastric cancer seem to suggest that a limit in efficacy has been reached for standard chemotherapy. Interesting data are expected from the development of targeted agents that, similarly to other cancer sites, showed appealing results in gastric cancer as well. Along with new effective therapeutic opportunities, better clinical and molecularly driven patient selection will represent the cornerstone of the global care for these patients.
引用
收藏
页码:175 / 185
页数:10
相关论文
共 101 条
[1]  
Hermans J(1993)Adjuvant therapy after resection for gastric cancer: meta-analysis of randomized trials J Clin Oncol 11 1441-1447
[2]  
Bonekamp JJ(1999)Adjuvant chemotherapy after resection for gastric cancer in non-Asian patients. Revisiting a meta-analysis of randomized trials Eur J Cancer 35 1059-1064
[3]  
Bon MC(2000)Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis for published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente) Ann Oncol 11 837-843
[4]  
Earle CC(2002)Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses Tumori 88 21-27
[5]  
Maroun JA(2008)Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC J Natl Cancer Inst 100 388-398
[6]  
Mari M(2005)Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801) Ann Oncol 16 1488-1497
[7]  
Floriani I(2002)Adjuvant chemotherapy in gastric cancer: 5-year results of a randomized study by the Italian Trials in Medical Oncology (ITMO) Group Ann Oncol 13 299-307
[8]  
Tinazzi A(2007)Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial J Natl Cancer Inst 99 601-607
[9]  
Panzini I(2001)Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725-730
[10]  
Gianni L(2005)Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients Br J Cancer 92 1051-1054